Revolution Medicines Inc (RVMD)

NASDAQ
15.65
-0.98(-5.89%)
After Hours
15.73
+0.08(+0.51%)
- Real-time Data
  • Volume:
    446,969
  • Day's Range:
    15.43 - 16.54
  • 52 wk Range:
    14.08 - 35.07

RVMD Overview

Prev. Close
16.63
Day's Range
15.43-16.54
Revenue
26.84M
Open
16.42
52 wk Range
14.08-35.07
EPS
-2.81
Volume
446,969
Market Cap
1.16B
Dividend (Yield)
N/A
(N/A)
Average Vol. (3m)
687,132
P/E Ratio
-
Beta
-
1-Year Change
-49.22%
Shares Outstanding
74,245,139
Next Earnings Date
Aug 15, 2022
What is your sentiment on Revolution Med?
or
Market is currently closed. Voting is open during market hours.

Revolution Medicines Inc Company Profile

Revolution Medicines Inc Company Profile

Employees
188

Revolution Medicines, Inc., a clinical-stage precision oncology company, focuses on developing therapies to inhibit frontier targets in RAS-addicted cancers. The company is developing RMC-4630, an inhibitor of SHP2, which is in Phase 1/2 clinical trial for the treatment of solid tumors, such as gynecologic and colorectal cancer tumors. It also develops RMC-5845, a selective inhibitor of SOS1, a protein that converts RAS (OFF) to RAS (ON) in cells; and RMC-5552, a hyperactivated selective inhibitor of mTORC1 signaling in tumors. In addition, the company is developing RMC-6291, a mutant-selective inhibitor of KRASG12C(ON) and NRASG12C(ON); and RMC-6236, a RAS-selective inhibitor of multiple RAS(ON) variants. Further, it develops RAS(ON) Inhibitors targeting KRASG13C(ON) and KRASG12D(ON). The company has a collaboration agreement with Sanofi for the research and development of SHP2 inhibitors, including RMC-4630. Revolution Medicines, Inc. was incorporated in 2014 and is headquartered in Redwood City, California.

Read More

Technical Summary

Type
5 Min
15 Min
Hourly
Daily
Monthly
Moving AveragesSellSellStrong SellStrong SellStrong Sell
Technical IndicatorsStrong BuyNeutralStrong SellStrong SellStrong Sell
SummaryNeutralNeutralStrong SellStrong SellStrong Sell
  • buy
    0
    • boy or skip?
      0
      • to entry or not to entry Mr. Ilya ?
        0
        • Looks good
          1